About the Company
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BTAI News
Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion
Begin your TipRanks Premium journey today. Bioxcel Therapeutics (BTAI) Company Description: BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The ...
BioXcel receives European patent for method of treating agitation in dementia using sublingual dexmedetomidine
BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, reported that the European Patent ...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel ...
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed ...
BioXcel Gets European Patent For Sublingual Dexmedetomidine To Treat Agitation In Dementia Patients
Friday said the European Patent Office (EPO) has granted patent covering a range of sublingual dosage forms of dexmedetomidine including films, wafers, and tablets to treat agitation in people with ...
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that ...
Q4 2023 BioXcel Therapeutics Inc Earnings Call
Colin Bristow; Analyst; UBS Samir Devani; Analyst; Rx Securities ...
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...
BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript
Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will include an update on the company's late stage clinical programs and the discussion of financial results for the ...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
Vimal Mehta: Thank you, everyone, for joining us today and for your continued interest in BioXcel Therapeutics. Have a great day. Operator: Thank you. That does conclude today’s teleconference ...
Loading the latest forecasts...